Press release
Dyslipidemia Therapeutics Market to Experience Significant Growth during the Forecast Period 2018 to 2028 | Major Players - Merck & Co., Pfizer, Novelion Therapeutics, Mylan, Abbott Laboratories, Novartis AG
According to a recently released Fact.MR study, revenues from dyslipidemia therapeutics market surpassed US$ 36 billion in 2018. Low-density lipoproteins held approximately two-thirds of revenues from dyslipidemia therapeutics worldwide in 2018. As high LDL levels have been associated with increased risks of heart attacks, strokes, and other cardiovascular problems in humans, governments around the world are launching various campaigns to raise awareness about the adverse impact of high LDL levels in the blood.The growing prevalence of cardiovascular disorders worldwide has prompted individuals to effectively manage their LDL levels. To capitalize on the current trends prevalent in the dyslipidemia therapeutics market, pharmaceutical companies continue to strive towards developing new and improved therapies to lower LDL levels, and effectively manage the percentage of other lipids in the blood. A range of new treatments such as combination therapies, gene editing, and novel target drugs are under development, particularly for dyslipidemia therapeutics.
Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=2928
Statins Persist as Preferred Drug Class for Dyslipidemia Therapeutics
Fact.MR estimates the sales of statins for dyslipidemia therapeutics to exceed $20,000 million in 2019. Statins continue to remain the first line of drugs prescribed by doctors to manage and treat dyslipidemia. Statin drugs are deemed useful in reducing LDL levels in humans, with their effectiveness in lowering LDL level being approximately 60%.
Clinical trials commend statin drugs to substantially reduce the risk of cardiovascular diseases, while stabilizing the blood vessels lining and reducing inflammation. Its ability to aid in blood vessel relaxation also contributes to lowering blood pressure in patients. Moreover, the growing prevalence of chemoprophylaxis, caused by consumption of statins is further expected to bolster demand for dyslipidemia therapeutics as a consequence.
Gains from other drugs for dyslipidemia therapeutics are expected to remain gradual, with demand arrested by concerns regarding side-effects of statins. There has been a notable rise in the development of alternative drugs, owing to certain health impacts associated with the consumption of statins including muscular pain, the onset of type 1 diabetes, and hemorrhagic stroke.
Browse Full Report on Dyslipidemia Therapeutics Market with in-depth TOC- https://www.factmr.com/report/2928/dyslipidemia-therapeutics-market
Non-statins and PCSK9 have witnessed widespread acceptance as an alternative to statins in dyslipidemia therapeutics. Furthermore, with research towards the use of nutraceuticals in clinical practices for dyslipidemia treatment intensifying, pharmaceutical companies are expected to witness significant opportunities in the functional food space.
North America Remains Lucrative for Dyslipidemia Therapeutics Market
The high consumption of fast food and stressful lifestyle of the North American population is one of the key reasons behind the growing incidences heart diseases in the continent. According to a report released by the Centers for Disease Control and Prevention (CDC) cardiovascular diseases were found to be the top cause of deaths in the United States of America in 2017. Another report from the CDC suggested a total of 48.6% US adults were eligible for statin therapy signifying the high prevalence of dyslipidemia in the country. Consequently, the sales of dyslipidemia therapeutic drugs are likely to stay high and the Fact.MR study estimates that the dyslipidemia therapeutics market will witness a growth of 2.9% through 2019.
Ask Our Industry Expert for more details on report- https://www.factmr.com/connectus/sample?flag=AE&rep_id=2928
Apart from North America, China presents lucrative opportunities for the dyslipidemia therapeutics market where the condition was identified as the key cause behind increasing incidences of cardiovascular diseases in the country. Following the discovery, the China Clinical Control of Dyslipidemia (CCCD) has been continuously releasing guidelines to reduce the condition in the country. These factors are likely to aid in the progression of the dyslipidemia therapeutics market in the country.
The Fact.MR report offers forecast of the dyslipidemia therapeutics market for the period 2018-2028. According to the report, the dyslipidemia therapeutics market is projected to record 2.5% CAGR through 2028.
To Buy Dyslipidemia Therapeutics Market Report, Check- https://www.factmr.com/checkout/2928/S
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - https://www.industrynewsanalysis.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dyslipidemia Therapeutics Market to Experience Significant Growth during the Forecast Period 2018 to 2028 | Major Players - Merck & Co., Pfizer, Novelion Therapeutics, Mylan, Abbott Laboratories, Novartis AG here
News-ID: 1579297 • Views: …
More Releases from Fact.MR

Global Data Catalog Market to Explode to $12.3 Billion by 2035, Driven by AI and …
The global Data Catalog Market is undergoing a rapid, technology-driven transformation, shifting its role from a passive metadata repository to an intelligent, active data intelligence platform. Propelled by the exponential growth in complex data and regulatory demands, the market is projected to reach an estimated US$12.32 Billion by 2035, according to leading market analysis.
This dramatic surge represents a Compound Annual Growth Rate (CAGR) of 21.9% throughout the forecast period of…

Content Delivery Network (CDN) Market to Reach USD 45.2 Billion by 2035 | Akamai …
The latest report on the Content Delivery Network (CDN) Market, forecasting robust growth propelled by surging global data traffic, the proliferation of streaming services, and the escalating demand for low-latency digital experiences. Valued at USD 18.5 billion in 2025, the global market is projected to expand at a compound annual growth rate (CAGR) of 9.4%, reaching USD 45.2 billion by 2035. This trajectory reflects the indispensable role of CDNs in…

Energy-based Aesthetic Devices Market Grow at a 10.8% CAGR by 2035 | Key Players …
latest report on the Energy-based Aesthetic Devices Market, forecasting robust growth propelled by surging demand for non-invasive dermatological treatments, technological innovations in laser, radiofrequency, ultrasound, and light-based systems, and heightened beauty awareness among consumers. Valued at USD 5,476.2 million in 2025, the global market is projected to expand at a compound annual growth rate (CAGR) of 10.8%, reaching USD 15,180.4 million by 2035. This trajectory reflects the market's pivotal role…

Global Surgical Tourniquets Market Projected to Nearly Triple, Reaching US$1.59 …
The global surgical tourniquets market is poised for significant expansion over the next decade, driven by a global surge in orthopedic surgeries, heightened demand for safer intraoperative blood control, and major technological advancements in pressure regulation systems. According to a comprehensive analysis by Fact.MR, the market, valued at US 670 millionin 2025,is forecasted to grow at a steady Compound Annual Growth Rate(CAGR) of 91.59 billion. This robust growth trajectory is…
More Releases for Dyslipidemia
Dyslipidemia Drugs Market - A Path to Wellness: Innovative Dyslipidemia Drugs fo …
Newark, New Castle, USA: The "Dyslipidemia Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Dyslipidemia Drugs Market: https://www.growthplusreports.com/report/dyslipidemia-drugs-market/8876
This latest report researches the industry structure, sales, revenue,…
Dyslipidemia Drugs Market - Defying Lipid Disorders, Inspiring Vitality: Innovat …
Newark, New Castle, USA - new report, titled Dyslipidemia Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Dyslipidemia Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Dyslipidemia Drugs market. The report offers an overview of the market, which…
Dyslipidemia - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Dyslipidemia - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.
Dyslipidemia is defined as elevation of the total cholesterol, the ""bad"" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a…
Emerging Opportunities in Dyslipidemia Drugs Market
The top five players in the global dyslipidemia drugs market are AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited, and Abbott Laboratories. The cumulative share of these players in the global market was valued at 74.4% in 2014. The exclusivity in the rights of blockbuster drugs has been the primary growth driver for these companies. Analysts predict that intensive research and development activities by these players…
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other…
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other…